{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:04:44Z","timestamp":1793084684301,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T00:00:00Z","timestamp":1488758400000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Dialysis guidelines in Japan recommend more frequent measurement of mineral metabolism markers than the Kidney Disease: Improving Global Outcomes guidelines. However, the extent to which frequent marker measurement contributes to achievement of target ranges and to therapy adjustment is unknown.<\/jats:p>\n                  <jats:p>Methods: This multicenter cohort study involved 3276 hemodialysis patients with secondary hyperparathyroidism. Data on laboratory measurements and drug prescriptions were collected every 3 months. Main exposures were frequencies of measuring serum calcium and phosphorus [weekly\/biweekly\/monthly (reference)] and serum parathyroid hormone (PTH) [monthly\/bimonthly\/trimonthly (reference)] levels. Outcomes were achievement of guideline-specified ranges of mineral metabolism markers when serum levels were over, and maintenance of ranges when levels were already within, respective specified ranges, use of intravenous vitamin D receptor activator (VDRA) and initiation of cinacalcet use. Associations were examined via generalized estimating equations.<\/jats:p>\n                  <jats:p>Results: When serum marker levels exceeded the target range, weekly measurement of calcium and phosphorus was positively associated with achievement of the guideline-specified calcium range [adjusted odds ratio (AOR): 1.57, 95% confidence interval (CI) 1.09\u20132.26] but not phosphorus range (AOR: 0.99, 95% CI 0.74\u20131.33). Monthly measurement of PTH was positively associated with achievement of the guideline-specified PTH range (AOR: 1.14, 95% CI 1.01\u20131.27). When serum marker levels were within the guideline-specified range, increased frequency of measurements was not associated with in-range maintenance of marker levels for any of the three mineral markers assessed. Regarding treatment regimen, relatively frequent measurement of serum calcium and phosphorus was positively associated with cinacalcet initiation and relatively frequent measurement of serum PTH with cinacalcet initiation and intravenous VDRA use.<\/jats:p>\n                  <jats:p>Conclusions: Our results suggest that increasing frequency of measurements is helpful when serum marker levels exceed the target range, partially via adjustment in the therapeutic regimen. We found no evidence that frequent measurements are helpful when mineral levels are already within target ranges.<\/jats:p>","DOI":"10.1093\/ndt\/gfw020","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T20:49:48Z","timestamp":1478292588000},"page":"534-541","source":"Crossref","is-referenced-by-count":11,"title":["Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy"],"prefix":"10.1093","volume":"32","author":[{"given":"Keitaro","family":"Yokoyama","sequence":"first","affiliation":[{"name":"1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kurita","sequence":"additional","affiliation":[{"name":"2Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, Fukushima, Japan"},{"name":"3Institute for Health Outcomes and Process Evaluation Research (iHope International), Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Fukuma","sequence":"additional","affiliation":[{"name":"3Institute for Health Outcomes and Process Evaluation Research (iHope International), Kyoto, Japan"},{"name":"4Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"},{"name":"5Center for Innovative Research for Communities and Clinical Excellence (CIRC2LE), Fukushima Medical University, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"6Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"7Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Onishi","sequence":"additional","affiliation":[{"name":"3Institute for Health Outcomes and Process Evaluation Research (iHope International), Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"8National Graduate Institute for Policy Studies, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"5Center for Innovative Research for Communities and Clinical Excellence (CIRC2LE), Fukushima Medical University, Fukushima, Japan"},{"name":"9Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"key":"2025102312492736700_gfw020C1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2025102312492736700_gfw020C2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"2025102312492736700_gfw020C3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"(Suppl 3)","key":"2025102312492736700_gfw020C4","first-page":"1","article-title":"KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"(Suppl)","key":"2025102312492736700_gfw020C5","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int"},{"key":"2025102312492736700_gfw020C6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"key":"2025102312492736700_gfw020C7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","article-title":"Consistent control of mineral and bone disorder in incident hemodialysis patients","volume":"3","author":"Danese","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312492736700_gfw020C8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","article-title":"Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients","volume":"17","author":"Taniguchi","year":"2013","journal-title":"Ther Apher Dial"},{"key":"2025102312492736700_gfw020C9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","article-title":"Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients","volume":"12","author":"Guideline Working Group, Japanese Society for Dialysis Therapy","year":"2008","journal-title":"Ther Apher Dial"},{"key":"2025102312492736700_gfw020C10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5414\/CN106657","article-title":"Optimal frequency of parathyroid hormone monitoring in chronic hemodialysis patients","volume":"76","author":"Greenberg","year":"2011","journal-title":"Clin Nephrol"},{"key":"2025102312492736700_gfw020C11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4009\/jsdt.44.557","article-title":"Results of the survey on practice patterns including MBD management at dialysis facilities: as part of the MBD-5D","volume":"44","author":"Yokoyama","year":"2011","journal-title":"J Jpn Soc Dial Ther"},{"key":"2025102312492736700_gfw020C12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1744-9987.2010.00906.x","article-title":"Mineral and Bone Disorders Outcomes Study for Japanese chronic kidney disease stage 5D patients: rationale and study design","volume":"15","author":"Fukuhara","year":"2011","journal-title":"Ther Apher Dial"},{"key":"2025102312492736700_gfw020C13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ndt\/gfg144","article-title":"Influence of PTH assay methodology on differential diagnosis of renal bone disease","volume":"18","author":"Reichel","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312492736700_gfw020C14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"BMJ"},{"key":"2025102312492736700_gfw020C15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1744-9987.2009.00789.x","article-title":"An overview of regular dialysis treatment in Japan (as of 31 December 2007)","volume":"13","author":"Nakai","year":"2009","journal-title":"Ther Apher Dial"},{"key":"2025102312492736700_gfw020C16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2215\/CJN.13081211","article-title":"Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study","volume":"7","author":"Fukagawa","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312492736700_gfw020C17","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2215\/CJN.11501210","article-title":"Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns","volume":"6","author":"Akizawa","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312492736700_gfw020C18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/nure.12115","article-title":"Dietary educational interventions for management of hyperphosphatemia in hemodialysis patients: a systematic review and meta-analysis","volume":"72","author":"Karavetian","year":"2014","journal-title":"Nutr Rev"},{"key":"2025102312492736700_gfw020C19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1744-9987.2011.00997.x","article-title":"Influence of the assay for measuring serum albumin on corrected total calcium in chronic hemodialysis patients","volume":"15","author":"Kato","year":"2011","journal-title":"Ther Apher Dial"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/3\/534\/24363585\/gfw020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/3\/534\/24363585\/gfw020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:50:21Z","timestamp":1761238221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/3\/534\/3059406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,3]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw020","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,3]]},"published":{"date-parts":[[2016,3,3]]}}}